Hot Blue Chip Stocks To Watch Right Now

&l;img class=&q; size-large wp-image-3387&q; src=&q;; alt=&q;Forbes – SSA logo&q; data-height=&q;683&q; data-width=&q;1200&q;&g;Social Security may be one of your largest assets. What and when you collect will make a huge difference to your lifetime benefits.

Today&a;rsquo;s column examines how bonuses are treated by the earnings test, sequencing retirement and spousal benefits, some potential ramifications of filing and suspending and how widow(er)&s;s benefits are calculated. Larry Kotlikoff is the founder and president of Economic Security Planning, a company that markets Maximize My Social Security, a Social Security benefits calculator referred to in this post.

See more &l;a href=&q;;&g;Ask Larry answers here&l;/a&g;.

Ask Larry about Social Security:

&l;iframe width=&q;760&q; height=&q;500&q; frameborder=&q;0&q; marginheight=&q;0&q; marginwidth=&q;0&q; src=&q;;&g;Loading…&l;/iframe&g;

Hot Blue Chip Stocks To Watch Right Now: 8×8 Inc(EGHT)

8×8, Inc. develops and markets telecommunications services for Internet protocol (IP), telephony, and video applications. The company offers 8×8 Virtual Office Business Telephone Service, an alternative to traditional private branch exchange systems that offers automated attendants to assist callers; extension-to-extension dialing services; direct inward dial; conference bridge, 3-way calling, music on hold, call park/pick-up, call transfer, hunt groups, and do not disturb services; voice mail, including email alerts and direct transfer to mailbox; call waiting/caller-ID; distinctive tone ringing; and optional receptionist console applications. Its products also include 8×8 Complete Contact Center, an integrated hosted call center solution that consists of skill-based routing, multi-media management, real time monitoring and reporting, voice recording and logging, historical reporting, interactive voice response, CRM integration, and contact and case management tools; 8×8 IP Telephones; 8×8 Virtual Meeting, a video Web conferencing service; and 8×8 Managed Hosting and Cloud-Based Computing Solutions. In addition, the company offers 8×8 Virtual Office Pro Unified Communications that allows subscribers to manage business communications functions online and delivers various tools, such as Microsoft Outlook contacts and corporate directory integration; virtual meeting; Virtual Office Mobile extension; fax; call recording; presence management; and a view of voicemails, recordings, FAX messages, calls, and chat history. The company markets its services under 8×8 brand to end users through direct sales force, Web site, and third party resellers primarily in the United States. As of June 30, 2011, it had approximately 25,000 business customers. 8×8, Inc. was founded in 1987 and is headquartered in Sunnyvale, California.

Advisors’ Opinion:

  • [By Max Byerly]

    Equities research analysts at William Blair started coverage on shares of 8X8 (NASDAQ:EGHT) in a research report issued to clients and investors on Wednesday, The Fly reports. The firm set a “buy” rating on the technology company’s stock.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on 8X8 (EGHT)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Anders Bylund]

    RingCentral (NYSE:RNG) led the way with a 26.3% surge, followed by 8×8 (NYSE:EGHT) at 13.8% and Vonage Holdings (NYSE:VG) scoring a 10.7% gain. All of these one-month returns crushed the broader market, as the S&P 500 benchmark notched just a 3% gain last month.

Hot Blue Chip Stocks To Watch Right Now: ZIOPHARM Oncology Inc(ZIOP)

ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. Its Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

The Company in collaboration with Intrexon Corporation is focused on chimeric antigen receptor T cell (CAR+ T) products. The Company in collaboration with Intrexon plans to develop treatments for graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT), which impairs the quality of life and survival of many recipients. Allogeneic HSCT is used for the treatment of various diseases, including hematological malignancies, immunological deficiencies, as well as non-malignant conditions. Approximately 40 to 60% of HSCT recipients develop GvHD, either acute or chronic, when immune (graft) cells in a transplant patient recognize their engrafted host as foreign and attack the patient’s (host) cells. Immunosuppressive agents and systemic steroids routinely used to treat GvHD have limited efficacy and toxicity. Human studies have shown that administration of low-dose subcutaneous IL-2 in patients with steroid-refractory GvHD acts through Tregs to ameliorate its manifestations.

Ad-RTS-IL-12 + veledimex

The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. The Company is evaluating Ad-RTS-IL-12 + veledimex, in brain cancer and breast cancer. It h! as developed an adenoviral vector, Ad-RTS-IL-12, administered intratumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Gene expression and subsequent IL-12 protein production is tightly controlled by the activator ligand veledimex.

Ad-RTS-IL-12 + veledimex for malignant glioma

The Company has initiated the Phase I study for malignant glioma. The Food and Drug Administration (FDA) granted orphan drug designation of Ad-RTS-IL-12 + veledimex for the treatment of malignant glioma.

Ad-RTS-IL-12 + veledimex for metastatic breast cancer and melanoma

The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. The Company has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer.

The Company competes with Novartis/University of Pennsylvania, Bluebird bio/Celgene/Baylor College of Medicine, Kite Pharma/National Cancer Institute, Juno Therapeutics/Fred Hutchinson Cancer Research Center/Memorial Sloan-Kettering Cancer Center/Seattle Children’s Research Institute, Cellectis/Pfizer, Adaptimmune/GSK, Celgene, NantKwest, Amgen, AstraZeneca, Bristol-Myers, Incyte, Merck and Roche.

Advisors’ Opinion:

  • [By Logan Wallace]

    A number of hedge funds have recently bought and sold shares of ZIOP. MSD Partners L.P. increased its position in ZIOPHARM Oncology by 222.1% during the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock valued at $20,544,000 after buying an additional 7,575,758 shares in the last quarter. FMR LLC bought a new position in ZIOPHARM Oncology during the 3rd quarter valued at approximately $1,647,000. Ibex Investors LLC bought a new position in ZIOPHARM Oncology during the 4th quarter valued at approximately $755,000. Bank of America Corp DE increased its position in ZIOPHARM Oncology by 198.1% during the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares in the last quarter. Finally, Old West Investment Management LLC increased its position in ZIOPHARM Oncology by 784.7% during the 4th quarter. Old West Investment Management LLC now owns 223,319 shares of the biotechnology company’s stock valued at $417,000 after buying an additional 198,077 shares in the last quarter. 40.12% of the stock is owned by institutional investors.

    WARNING: “ZIOPHARM Oncology (ZIOP) Stock Price Up 8.9%” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at

    ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

  • [By Motley Fool Transcribers]

    Ziopharm Oncology Inc (NASDAQ:ZIOP)Q42018 Earnings Conference CallMarch 05, 2019, 4:30 p.m. ET

    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:


  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Keith Speights]

    Strongbridge Biopharma (NASDAQ:SBBP), Endo International plc (NASDAQ

Leave a Reply

Your email address will not be published. Required fields are marked *